Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
April 10, 2026 17:02 ET | Source: Replimune, Inc. WOBURN, Mass., April…
J.S. Held Strengthens Cross-Disciplinary Response to Artificial Intelligence (AI) Disputes
Delivering technical clarity, financial calculus, and courtroom credibility in AI-related litigation.NEW YORK,…
Pivotal Launches eVTOL Emergency Response Operations with Hyde County, North Carolina and Code Blue Resources
PALO ALTO, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Pivotal, the market…
Expedience Software Recognized as a Representative Vendor in the 2025 Gartner Market Guide for RFP Response Management Applications
MANCHESTER, N.H., March 04, 2026 (GLOBE NEWSWIRE) -- Expedience Software, a leading…
Coway Issues Official Response to Align Partners’ Second Proposal, Reaffirms Commitment to Shareholders and Sustainable Growth
Coway proves record-breaking growth through core strategies led by Chairman Junhyuk BangThe…
Phaos Technology Holdings (Cayman) Limited Provides Response to Unusual Market Action
SINGAPORE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Phaos Technology Holdings (Cayman) Limited,…
Atos positioned as a Leader in the IDC MarketScape: Middle East Managed Detection and Response (MDR) 2025 Vendor Assessment
Press Release Atos positioned as a Leader in the IDC MarketScape™: Middle…
Pharming Group receives Complete Response Letter from U.S. FDA for sNDA for Joenja (leniolisib) in children aged 4 to 11 years with APDS
Leiden, the Netherlands, February 1, 2026: Pharming Group (Euronext: PHARM; Nasdaq: PHAR)…
ACTFORE Secures Patent for Template Identification and Matching Technology, Transforming Large-Scale Document Analysis in Breach Response
RESTON. Va., Jan. 30, 2026 (GLOBE NEWSWIRE) -- ACTFORE, a leading provider…
Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response
• Patient 1 of Cohort 1 has now completed the 24-month follow-up…
